|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 329.90 DKK | -1.76% |
|
+2.37% | +1.43% |
| 06:18pm | Abbott investigates two separate cyber incidents, says no operations affected | RE |
| 07-17 | Novo Nordisk to launch lower-cost Ozempic copy in South Africa | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 227B | |||||
| 1,043B | |||||
| 602B | |||||
| 449B | |||||
| 327B | |||||
| 279B |
- Stock Market
- Stocks
- NOVO B Stock
- Charts Novo Nordisk A/S
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition